Concurrent Use of Amitriptyline and Nurtec (Rimegepant)
Yes, amitriptyline and Nurtec (rimegepant) can be used concurrently without significant safety concerns, as there are no documented pharmacokinetic or pharmacodynamic interactions between these medications.
Safety Profile
The concurrent use of these medications is safe based on the following evidence:
No drug-drug interaction exists: The FDA label for Nurtec specifically addresses drug interactions and does not list amitriptyline or tricyclic antidepressants as contraindicated or requiring dose adjustments 11. The primary interactions of concern with rimegepant involve CYP3A4 inhibitors/inducers and P-glycoprotein inhibitors—amitriptyline does not significantly affect these pathways in a clinically relevant manner.
Different mechanisms of action: Amitriptyline works primarily through norepinephrine and serotonin reuptake inhibition, while rimegepant is a CGRP receptor antagonist. These distinct mechanisms mean they do not compete for the same receptors or metabolic pathways 23.
Clinical trial data supports combination use: Recent guidelines acknowledge that patients may use preventive medications (like amitriptyline) concurrently with acute treatments (like rimegepant) 44. In fact, clinical studies of rimegepant included participants "with or without concomitant use of medication to prevent migraine" 4, demonstrating safety in real-world polypharmacy scenarios.
Monitoring Recommendations
While no specific monitoring is required for the drug interaction itself, standard monitoring for each medication individually should continue:
For Amitriptyline:
- Monitor for anticholinergic effects (dry mouth, constipation, urinary retention)
- Assess for sedation and cognitive effects
- ECG monitoring if cardiac risk factors present (QTc prolongation)
For Rimegepant:
- Monitor for hypersensitivity reactions (though rare, <1% incidence) 1
- Watch for medication overuse headache if using rimegepant >10 days per month for acute treatment 4
- No hepatic monitoring is routinely required, though aminotransferase elevations >3x ULN occurred in 0.9% of patients in long-term studies 5
Clinical Context and Practical Considerations
This combination makes clinical sense from a therapeutic standpoint: amitriptyline serves as a preventive agent (recommended as first-line by the 2025 ACP guidelines 6), while rimegepant can be used either for acute treatment or as an alternative preventive option. The 2025 ACP guidelines specifically recommend trying medications like amitriptyline before escalating to CGRP antagonists like rimegepant due to cost considerations 6.
Key caveats:
- If using rimegepant for prevention (every other day dosing), ensure the patient understands they can still use it acutely on non-scheduled days, with a maximum of one dose per calendar day 5
- Amitriptyline's metabolism can be affected by other medications (CYP2D6 inhibitors like some phenothiazines 7), but rimegepant is not among them
- The combination does not increase cardiovascular risk—rimegepant does not cause vasoconstriction unlike triptans 23
No dose adjustments are needed when initiating or combining these medications. The standard dosing remains: amitriptyline typically 25-150 mg daily for migraine prevention, and rimegepant 75 mg as needed for acute treatment or every other day for prevention.